Armata Pharmaceuticals, Inc.
NYSE American ARMP
Armata Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -4.35 M
-
Armata Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -5.29 M, a -82.76% change year over year.
-
Armata Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -2.89 M, a -100.69% change year over year.
-
Armata Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -1.44 M, a -273.58% change year over year.
-
Armata Pharmaceuticals, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -386.00 K, a -113.78% change year over year.
| Date | Net Cash Used For Investing Activities | Net Cash Used Provided By Financing Activities | Dividends Paid | Capital Expenditure |
|---|
| CEO | Dr. Deborah L. Birx M.D. |
| IPO Date | May 20, 1994 |
| Location | United States |
| Headquarters | 4503 Glencoe Avenue |
| Employees | 66 |
| Sector | Health Care |
| Industries | |
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Past 5 years
USD 2.13
StockViz Staff
January 15, 2025
Any question? Send us an email